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Objective: To estimate the cost-effectiveness of using a liquid human milk fortifier (LHMF) 
compared to a powdered human milk fortifier (PHMF) in preterm infants in the US from the 
perspective of third-party payers and parents.
Methods: This was a decision modelling study using patient data obtained from a random-
ized controlled trial comparing a LHMF with a PHMF in preterm infants, supplemented with 
additional data obtained by performing a chart review among 79% of the trial patients. The 
model estimated the cost-effectiveness of LHMF versus PHMF in US$ at 2014/2015 prices.
Results: More infants in the LHMF group were discharged home (92% versus 89%) and more 
infants in the PHMF group were transferred to another unit (9% versus 5%). Gestational age 
was an independent predictor for being discharged home (odds ratio of 2.18; p=0.006 for each 
week of gestational age). Mean length of neonatal intensive care unit (NICU) stay was 1 day 
less in the LHMF than the PHMF group (62.3 versus 63.4 days), but mean length of NICU stay 
among infants who developed NEC or sepsis was 79.3 days and 61.2 days in the PHMF and 
LHMF groups, respectively. Total management cost up to discharge was $10,497 per infant less 
in the LHMF group than the PHMF group ($240,928 versus $251,425).
Conclusion: Using LHMF instead of PHMF in preterm infants enabled resources to be freed-up 
for alternative use within the system. There is no health economic reason why LHMF should 
not be used in preference to PHMF in the NICU.
Keywords: cost-effectiveness, milk fortifiers, neonatal intensive care, preterm infants, US
Introduction
Fortification of human milk is indicated for supplying the required nutrients to sup-
port the rapid rate of growth and bone mineralization in preterm infants.1 HMFs are 
nutritional supplements designed to increase total energy, protein, and micronutrient 
delivery to preterm infants. The primary benefits of human milk fortification include 
improved growth, bone mineralization, and protein status.2–4 It is common practice in 
NICUs to add liquid or powdered fortifiers to an infant’s feed to better meet the protein 
needs of smaller preterm infants. However, powdered HMFs fail to meet the recom-
mended safety guidelines designed to decrease the risk of transmission of pathogens, 
such as Cronobacter sakazakii and other infectious complications, in the NICU.5–7 
Consequently, during the last decade, there has been a gradual transition to sterile 
liquid nutritionals in the neonatal environment. Unlike powdered nutritionals, LHMFs 
may have the advantage of sterility and simpler liquid–liquid mixing with human milk. 
A recent multicenter, third-party-blinded, randomized controlled study, in which 
the clinical investigators, all NICU personnel and sponsor personnel who were 
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monitoring the study were unaware of treatment assign-
ment, compared a LHMF with a PHMF in preterm infants to 
evaluate the growth, tolerance, and safety.8 One hundred and 
fifty preterm infants with a body weight ≤1,250 g who were 
fed expressed and/or donor breast milk were randomized to 
receive a PHMF or LHMF for 28 days. The study found that 
the achieved weight and linear growth rate were significantly 
higher in the LHMF group (p=0.04 and p=0.03, respectively). 
Among the infants who adhered closely to the protocol, the 
LHMF group achieved a significantly higher weight, length, 
head circumference and linear growth rate than infants in 
the PHMF group (p=0.004, p=0.003, p=0.04, and p=0.01, 
respectively). However, there were no differences in measures 
of feeding tolerance or days to achieve full feeding volumes. 
Prealbumin, albumin, and blood urea nitrogen were all higher 
in the LHMF group (p<0.05). There was no difference in the 
incidence of confirmed sepsis or NEC. Hence, use of LHMF 
in preterm infants instead of PHMF was found to improve 
growth and afford a safe alternative. 
The comparative health economic impact of these two 
fortifiers is unknown, and therefore, dietetic choices are based 
largely on their safety, nutritional value, and purchase cost. 
Hence, the objective of the current study was to use data from 
the patients who participated in the aforementioned trial to 
estimate the cost-effectiveness of using LHMF compared to 
PHMF in preterm infants in the US, from the perspective of 
third-party payers and parents.
Methods
Study design
This was a retrospective modelling study using patient data 
obtained from the aforementioned clinical trial,8 together 
with additional data from a sample of the trial patients sub-
sequently obtained by performing a chart review. 
Chart review
All 14 centers that participated in the trial8 were invited to 
participate in the chart review. However, only 9 centers agreed 
to participate. The other 5 centers chose not to participate 
because either the principal investigator had left, or there was 
a lack of interest, or it was not feasible to retrieve the patients’ 
records, or too few patients were enrolled in the original trial.
Hence, IRB approval was obtained to undertake the chart 
review at 9 of the 14 clinical trial centers from The New 
Hanover Regional Medical Centre Institutional Review Board 
(Reference # 1410-5). Approval was given for a member of 
the clinical staff at each center to conduct the chart review 
and to then forward the collected data, once anonymized, to 
the study’s authors in order for them to perform an economic 
analysis. The chart review recorded:
•	 Length of stay in the NICU; 
•	 Body weight at discharge;
•	 Body length at discharge;
•	 Head circumference at discharge;
•	 Disposition on discharge.
Statistical analyses
The ITT population from the original trial was balanced 
and there were no significant differences in baseline vari-
ables between the two groups. ANCOVA found that the 
baseline variables in the two treatment groups in the chart 
review population were balanced and no adjustments were 
necessary. 
Differences in health outcomes and resource use between 
the two groups in the chart review population were tested 
for statistical significance using a Mann-Whitney U-Test, 
independent samples t-test, and a Chi-Square test. Logistic 
regression was used to investigate relationships between 
baseline variables and the probability of being discharged 
home. Multiple linear regression was also used to assess the 
impact of patients’ baseline variables on resource use and 
clinical outcomes. All statistical analyses were performed 
using SPSS Statistics (v22.0; IBM Corporation, Armonk, 
NY, USA).
Economic model
A decision model (Figure 1) was constructed using TreeAge 
Pro 2009 (TreeAge Software Inc., Williamstown, MA, USA) 
depicting the management of preterm infants who were man-
aged with LHMF or PHMF. The model was populated with 
patient-level data from the aforementioned clinical trial,8 and 
additional data obtained from the chart review. The period 
of the model was up to discharge from the NICU or death if 
that occurred earlier. The primary measure of clinical effec-
tiveness in the model was the probability of infants being 
discharged home. 
Unit costs obtained from the MarketScan Commercial 
Claims Database, and uprated to 2014/2015 prices using 
the US inflation indexes, were assigned to the estimates of 
resource use in the model in order to calculate the cost of 
managing patients in each group at 2014/2015 prices.
The cost-effectiveness of LHMF versus PHMF was 
calculated as: the difference in the cost of patient manage-
ment between the two groups divided by the difference in 
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Cost-effectiveness of a liquid human milk fortifier
groups, expressed as the incremental cost for each additional 
infant who was discharged home. If one fortifier improved 
the probability of being discharged home for less cost, it was 
considered a dominant (ie, cost-effective) treatment.
Sensitivity analyses
To assess uncertainty within the model, probabilistic sensitiv-
ity analysis was undertaken (10,000 iterations of the model) 
to estimate the distribution of 1) costs and 2) probabilities 
of being discharged home. This was achieved by simultane-
ously varying the probabilities, clinical outcomes, resource 
use values and unit costs within the model. Outputs from 
these analyses were used to estimate the probability of being 
cost-effective at different thresholds of incremental cost per 
additional infant who was discharged home.
In addition, deterministic sensitivity analyses were per-
formed to identify how the incremental cost-effectiveness 
of LHMF compared to PHMF would change by varying 
different parameters in the model. 
Results
Infants’ characteristics
From the chart review, additional data were obtained on 79% 
of the patients who were in the ITT cohort. The baseline 
characteristics of infants in the chart review cohort were not 
significantly different from the whole ITT cohort. Any dif-
ferences between the ITT and chart review populations can 
be explained by different sample sizes, implying the chart 
review population was sufficiently representative of all the 
infants who participated in the trial (Table 1). 
Completed 28 days treatment
Discharged home




Transferred to another unit
Transferred to another unit























Figure 1 Decision model depicting the management of infants in the chart review population. 
Note: Numbers denote the probability of an infant following a particular path.
Abbreviations:  LHMF, liquid human milk fortifier; PHMF, powdered human milk fortifier.
Table 1 Infants’ baseline characteristics
ITT population Chart review population
LHMF PHMF LHMF PHMF
Sample size 74 72 57 59
Percentage female 50% 56% 51% 53%
Mean (±SD) gestational age per infant (weeks) 27.9±1.4 27.7±1.8 27.6±1.5 27.1±1.8
Mean (±SD) body weight per infant at day 0 (g) 1014.7±171.6 987.1±197.7 1140.3±176.8 1082.8±188.8
Mean (±SD) body length per infant at day 0 (cm) 36.1±3.3 35.6±2.9 35.8±3.7 35.4±3.1
Mean (±SD) head circumference per infant at day 0 (cm) 25.0±1.7 25.1±1.7 25.1±1.7 24.9±1.8
Mean (±SD) number of sachets/vials of fortifier per infant over 28 days of treatment 293.4±222.0 297.0±216.8 298.8±238.9 306.5±230.5
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Probability of being discharged home
The probability of infants being discharged home was not 
significantly different between the two groups, although 
marginally more infants in the LHMF group were discharged 
home (0.92 versus 0.89) or died (0.03 versus 0.02) and mar-
ginally more infants in the PHMF group were transferred to 
another unit (0.09 versus 0.05).
Binary logistic regression showed, as expected, that gesta-
tional age was an independent predictor for being discharged 
home (odds ratio of 2.18 [95% CI: 1.25; 3.70]; p=0.006 for 
each week of gestational age).
Health outcomes and resource use
At the time of discharge from the NICU, there were no 
significant differences in body weight, body length or head 
circumference between the two groups (Table 2). Addition-
ally, there was no significant difference in the mean length of 
stay in the NICU between the two groups (Table 2).
There was no significant difference (p>0.25) in the inci-
dence of infants who developed NEC or sepsis between the 
two groups either in the trial8 or the chart review population 
(Table 2). However, in the PHMF chart review population 
one infant had a combination of sepsis and NEC, whereas in 
the LHMF group three infants had a combination of sepsis 
and NEC.  Of these, one infant in the LHMF group had 
multiple episodes of sepsis. All the other affected infants 
either had one episode of sepsis or NEC. The mean length of 
NICU stay of infants who developed these comorbidities was 
79.3 days in the PHMF group and 61.2 days in the LHMF 
group. In contrast, the length of NICU stay of infants who 
did not develop NEC or sepsis was a mean of 62.7 days in 
both groups.
There were no differences in length of stay in the NICU 
between the two groups when stratified according to gesta-
tional age. Those infants with a gestational age ≤27 weeks 
had a length of stay in the NICU of a mean of 74–76 days per 
infant, irrespective of fortifier. In comparison, those infants 
with a gestational age >27 weeks had a length of stay in the 
NICU of a mean of 51–53 days per infant. 
Linear regression showed that gestational age, head 
circumference at birth, and body length at birth were inde-
pendent predictors of length of stay in the NICU. The length 
of stay in the NICU would be reduced by:
•	 4 days for each week of gestational age (p<0.001);
•	 2.5 days for each cm of head circumference at the start 
of treatment (p=0.001);
•	 1 day for each cm of body length at the start of treatment 
(p=0.004).
Head circumference and body length are surrogates for 
the type of intrauterine growth and relate directly to ges-
tational age. Hence, they relate to length of stay. Feeding 
strategies can also influence head circumference and body 
length after birth, both of which impact on body weight. 
Consequently, body weight is one of the major factors a 
neonatologist considers when deciding to discharge an infant 
from the NICU.
Health care cost of infant management
The total management cost up to discharge was 
$240,928±36,979 per LHMF-treated infant  and 
$251,425±38,488 per PHMF-treated infant. Hence, the 
total cost of infant management up to the time of discharge 
was $10,497 per infant less in the LHMF group than the 
PHMF group (Table 2).
The total cost to third-party payers was $236,922 per 
LHMF-treated infant and $246,886 per PHMF-treated infant. 
The corresponding cost to parents was $4,006 and $4,540 
per infant in the LHMF and PHMF groups, respectively. 
Hence, the cost per infant to third-party payers and parents 
was $9,964 and $533, respectively less in the LHMF group 
than the PHMF group (Table 2). 
The primary cost driver was length of stay in the NICU, 
accounting for 99% of the cost to third-party payers.  Fortifiers 
accounted for <1% of costs to third-party payers, and  parents’ 





Mean (±SD) body weight per infant at 
discharge (g)
2295.2±595.3 2203.7±581.4
Mean (±SD) body length per infant at 
discharge (cm)
44.2±3.4 43.8±4.1
Mean (±SD) head circumference per 
infant at discharge (cm)
31.6±2.6 31.5±3.6
Percentage with NEC or sepsis 21% 17%




Mean (±SD) NICU cost per infant to 
third-party payers
$236,394.90 $246,558.50
Mean (±SD) fortifier cost per infant to 
third-party payers 
$527.00 $327.00
Mean (±SD) NICU cost per infant to 
parents
$4,006.10 $4,539.50
Mean (±SD) total gross cost per 
infant
$240,928.00 $251,425.00
Abbreviations: LHMF, liquid human milk fortifier; NEC, necrotising enterocolitis; 
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Cost-effectiveness of a liquid human milk fortifier
costs account for 2% of the gross cost. Parents do not con-
tribute to the cost of fortifiers.
Since the mean length of NICU stay of infants who devel-
oped NEC or sepsis was 18.1 days more in the PHMF group, 
the total cost of management of these infants was $304,428 
and $219,085 per infant in the PHMF and LHMF groups, 
respectively. In contrast, the cost of managing infants who did 
not develop NEC or sepsis was a mean of $242,548 per infant. 
The cost of managing infants with a gestational age 
≤27 weeks was a mean of $300,000 per infant irrespective of 
treatment group, which was reduced to a mean of $194,000 
per infant who had  a gestational age >27 weeks. 
Cost-effectiveness analysis 
Proportionally more infants in the LHMF group were dis-
charged home compared to those in the PHMF group. Addi-
tionally, feeding infants with LHMF reduced  management 
costs when compared to feeding infants with PHMF. Hence, 
use of LHMF instead of PHMF was found to be the domi-
nant strategy, because it improved outcome for less cost, 
from the perspective of both third-party payers and parents 
(Table 3).
Sensitivity analyses 
Probabilistic sensitivity analyses estimated the distribution 
of expected costs and probabilities of being discharged 
home (Figure 2). Using these distributions, the probability 
of LHMF being cost-effective was found not to exceed 0.6 
(Figure 3). In other words, no more than 60% of a cohort is 
expected to be cost-effectively treated with LHMF, and that 
up to 40% of a cohort could be cost-effectively treated with 
PHMF, from a gross perspective.
Deterministic sensitivity analyses (Table 4) showed 
that the results are extremely sensitive to the probability of 







Cost-difference Difference in 
probability of 
being discharged home
Incremental cost for 
each additional infant 
being discharged home
Gross perspective
LHMF $240,928 0.92 Dominant
PHMF $251,425 0.89 –$10,497 0.03 Dominated
Third-party payers’ 
perspective
LHMF $236,922 0.92 Dominant
PHMF $246,886 0.89 –$9,964 0.03 Dominated
Parents’ perspective
LHMF $4,006 0.92 Dominant
PHMF $4,540 0.89 –$534 0.03 Dominated
Note: Costs in US$ (at 2014/2015 prices).

























0.002 0.007 0.012 0.017 0.022 0.027
Incremental probability of being discharged home
0.032 0.037 0.042 0.047 0.052
Figure 2 Scatterplot of the incremental cost-effectiveness of LHMF compared with PHMF (10,000 iterations of each model). 
Notes: A beta distribution was used to represent uncertainty in probability values and a log-normal distribution was used to represent uncertainty in clinical outcomes and 
resource use estimates, by assuming a 5% standard deviation around the mean values. Unit costs were varied randomly according to a gamma distribution by assuming a 10% 
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Cost-effectiveness willingness to pay threshold 
Figure 3 Cost-effectiveness acceptability curve.
Note: Costs in US$ (at 2014/2015 prices).
Table 4 Deterministic sensitivity analyses
Scenario Base case 
value
Third-party payers’ perspective Parents’ perspective
Probability of LHMF-treated 
infants being discharged home 
(range 0 to 1.0)
0.92 PHMF becomes the cost-effective (dominant) 
option when the probability falls below 0.9
PHMF becomes the cost-effective 
(dominant) option when the probability falls 
below 0.9
Probability of PHMF-treated 
infants being discharged home 
(range 0 to 1.0)
0.89 LHMF remains the cost-effective (dominant) 
option below a probability of 0.9
LHMF remains the cost-effective (dominant) 
option below a probability of 0.9
Length of NICU stay among 
LHMF-treated infants (range from 
50% below to 50% above the base 
case value)
62.3 days As the length of NICU stay of LHMF-treated 
infants increases above the base case value, 
LHMF is no longer cost-effective since the 
incremental cost for each additional infant 
discharged home is >$486,000
As the length of NICU stay of LHMF-treated 
infants increases by above the base case 
value, LHMF is no longer cost-effective since 
the incremental cost for each additional 
infant discharged home is >$9,700
Length of NICU stay among 
PHMF-treated infants (range from 
50% below to 50% above the base 
case value)
63.4 days As the length of NICU stay of PHMF-treated 
infants decreases below the base case value, 
LHMF is no longer cost-effective since the 
incremental cost for each additional infant 
discharged home is >$524,000
As the length of NICU stay of PHMF-treated 
infants decreases below the base case value, 
LHMF is no longer cost-effective since the 
incremental cost for each additional infant 
discharged home is >$13,500
Number of LHMF vials (range from 
50% below to 50% above the base 
case value)
301 vials LHMF remains the cost-effective (dominant) 
option
N/A
Number of PHMF sachets (range 
from 50% below to 50% above the 
base case value)
305 sachets LHMF remains the cost-effective (dominant) 
option
N/A
Cost per day in the NICU for 
infants who are discharged home 
(range $3,000 to $4,000 per day)
$3,668 per day LHMF remains the cost-effective (dominant) 
option
LHMF remains the cost-effective (dominant) 
option
Cost per day in the NICU for 
infants who are transferred to 
another unit (range $6,500 to 
$7,500 per day)
$7,061 per day LHMF remains the cost-effective (dominant) 
option
LHMF remains the cost-effective (dominant) 
option
Note: Costs in US$ (at 2014/2015 prices).
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Cost-effectiveness of a liquid human milk fortifier
being discharged home and the length of stay in the NICU. 
Changes in these values could result in PHMF becoming the 
cost-effective option. Conversely, the results are insensitive 
to changes in quantity of fortifier fed to the infants.
Discussion 
This retrospective modelling study depicted the manage-
ment of preterm infants with a body weight ≤1,250 g and 
 gestational age ≤30 and 3/7 weeks who were managed with 
either a LHMF or a PHMF. The economic analysis was based 
on data obtained from a chart review of 79% of the ITT cohort 
from the aforementioned study.8 The baseline characteristics 
of the chart review population were found to be representative 
of all the infants in the ITT cohort. 
There were no differences in achieved body weight, 
body length, or head circumference at discharge between 
the LHMF and PHMF groups. This is in contrast with the 
significant differences in those parameters which were shown 
at the end of the 28-day study period in the original trial.8 This 
may reflect the fact that the sample size of the chart review 
population was smaller and once the study period ended in 
the original trial, all infants reverted to a nutritional regimen 
that included a lower intake of protein and potential energy, 
at a time when many infants were still below 34–35 weeks 
of corrected age with higher nutritional demands.  Notwith-
standing this, infants in the LHMF group had nonsignificant 
lower birth lengths and birth weights. Additionally, the LHMF 
had ~20% more protein than the PHMF.8 However, it is highly 
unlikely that these differences had any bearing on length of 
stay and the decision to discharge an infant from the NICU 
during the blinded study. Moreover, the fortification of the 
LHMF was initiated almost a full day later, which would have 
put the infants in that group at a relative disadvantage. Body 
weight at discharge was not significantly different between 
the two groups, but was almost 100 g higher in the LHMF 
group. This difference was much higher than that observed 
at birth and is clinically important, since body weight is a 
far more important determinant of the time of discharge than 
some other variables.
Whilst this study focused on the cost-effectiveness of 
alternative human milk fortifiers, there are additional health 
economic benefits associated with using human milk, particu-
larly in relation to infants’ morbidities.9 Infants born with a 
very low birth weight (<1,500 g) are at high risk of mortality 
and are reported to be some of the most expensive patients in 
a US hospital.10 Such infants are susceptible to prematurity-
related morbidities, such as late-onset sepsis and NEC, which 
have health economic consequences.9 Human milk has been 
shown to reduce both the incidence and severity of some of 
these morbidities and, therefore, has an indirect impact on 
reducing the cost of NICU hospitalization.9 
A diagnosis of NEC in very low birth weight infants has 
been shown to impose a significant additional financial bur-
den to individual patients as well as the neonatal community 
as a whole.11 The mean length of NICU stay of infants in our 
chart review cohort who had NEC or sepsis was 79.3 days 
in the PHMF group and 61.2 days in the LHMF group. 
 Moreover, the difference in length of stay between infants 
without NEC or sepsis and those with NEC or sepsis in the 
LHMF group was similar. Although these findings were based 
on a small number of subjects, they were not truncated due to 
death and thus represent real values. A larger cohort of infants 
would need to be studied to confirm this preliminary finding. 
The mean cost of care for infants in our chart review cohort 
who had NEC or sepsis was $304,428 in the PHMF group 
and $219,085 in the LHMF group. In contrast, the cost of 
care for the infants who did not develop NEC or sepsis was 
a mean of $242,548 per infant. Feeding extremely premature 
infants in the NICU with a 100% human milk-based diet that 
includes mother’s milk fortified with donor human milk-
based HMF compared with bovine milk-based supplements 
may prevent NEC12,13 and thereby reduce hospital stay14 and 
generate savings in medical care resource use.12,13 
The infants in our study were located across four states 
(Florida, Illinois, North Carolina, Virginia), had a mean ges-
tational age of 27 weeks per infant and a length of stay in the 
NICU of a mean of 62–63 days per infant. However, those with 
a gestational age ≤27 weeks had a length of stay in the NICU 
of a mean of 74–76 days per infant irrespective of treatment 
group, compared to 51–53 days per infant with a gestational 
age >27 weeks. Furthermore, regression analysis showed that 
the length of stay in the NICU was reduced by 4 days for each 
week of gestational age. This is consistent with the findings 
of others. In a Californian study the mean length of stay of 
neonatal care ranged from 83.3 days for those infants with a 
gestational age of 25 completed weeks, to 2.6 days for those 
infants with a gestational age of 37 completed weeks.15 It is 
also concordant with an analysis of a US national database 
which found that the length of hospital stay in late preterm 
infants is associated with multiple demographic and clinical 
factors.16 Factors associated with a length of stay of >3 days 
included gestational age of <35 weeks and birth weight of 
<2,500 g.16 In the Californian study, the costs of hospital stay 
decreased with gestational age from a median of $279,286 at 
24 weeks to $761 at 37 weeks (uprated to 2015 prices).15 In 
our study, the cost of managing infants with a gestational age 
≤27 weeks was a mean $300,000 per infant irrespective of 
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per infant with a gestational age >27 weeks. Another US study 
which compared feeding an entirely human milk-based diet 
with bovine-based fortifier and maternal milk or a mix of 
maternal milk, bovine-based fortifier and formula or formula-
fed infants found the total cost of hospitalization to range from 
$237,929 to $345,024 (uprated to 2015 prices) per infant.17 In 
comparison, the total gross cost per infant in our chart review 
cohort was $240,928 in the LHMF group and $251,425 in the 
PHMF group. Whilst this cost-difference is relatively small 
(only 4%), the provision of a fortifier that adheres to new 
infection control guidelines and provides improved nutrition8 
without increasing costs is advantageous.
Our study is subject to several limitations. The multicenter 
trial8 was designed to assess the efficacy and safety of LHMF 
in preterm infants receiving human breast milk and not to 
assess its relative cost-effectiveness. Only infants for whom 
resource use data were obtained have been included in the 
economic analysis, although the baseline characteristics of 
the chart review cohort were similar to those of the patients in 
the ITT cohort.8 No information was available on the destina-
tion and associated costs of patients who were transferred and 
the study does not consider the costs and consequences of the 
infants once they have left the NICU. However, proportionally 
more infants in the PHMF group were transferred to other 
units and more infants in the LHMF group were discharged 
home. Consequently, if the management cost in the stepdown 
units had been included in the analysis, the cost-difference 
between the two groups would probably be greater than our 
estimated value of $10,497 per infant. Since more infants in 
the PHMF group were transferred to another facility, even if 
all these transfers were to a lower acuity facility for convales-
cence, the cost of managing infants would still be less in the 
LHMF group than the PHMF group. Furthermore, this was 
a blinded study and the clinicians who made the discharge 
decisions did not know which fortifier each infant received. 
Hence, the decision to discharge home or to another facility 
is unlikely to be subject to bias. Notwithstanding this, there 
was a 1-day nonsignificant difference in the mean length of 
NICU stay between the 2 groups, which accounted for the 
majority of the cost-difference. The possibility that other 
factors may contribute to economic differences between the 
two treatments cannot be excluded. 
The analysis excluded the indirect costs incurred by 
society as a result of employed parents taking time off work 
and nontreatment-related costs incurred by parents. Also 
excluded are changes in health-related quality of life and 
improvements in general well-being of the infants and their 
parents as well as parents’ preferences. Consequently, this 
study may have underestimated the relative cost-effectiveness 
of LHMF. The study was performed from the perspective of 
third-party payers and parents in the US. Therefore, general-
izing this study’s results to other publicly-funded health care 
systems would be challenging.
Conclusion
Within the study’s limitations, using LHMF instead of 
PHMF in preterm infants enables resources to be freed up 
for alternative use within the system and there is no health 
economic reason why LHMF should not be used in prefer-
ence to PHMF in the NICU.
Moreover, preterm births in the US impose a substantial 
burden on society.18 Hence, any intervention that reduces 
the use of health care resources, such as LHMF, has the 
potential to reduce this burden and such savings could be 
used to enhance the use of breast milk as the primary source 
of nutrition for all babies.
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